Save up -80% on Anakinra
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Kineret
|$3,825.69||28 syringes 100mg/0.67ml|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Kineret coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Anakinra every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Anakinra volume of distribution
In subjects with RA, maximum plasma concentrations of anakinra occurred at 3 to 7 hours after subcutaneous administration of anakinra at clinically relevant doses (1 to 2 mg/kg; n = 18). The plasma concentration decreased with no discernible distribution phase and the terminal half-life ranged from 4 to 6 hours.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Anakinra
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.
Anakinra mechanism of action
Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.
Dosage forms of Anakinra
|Injection, solution||subcutaneous||100 mg/.67mL|
|Solution for injection||Subcutaneous use||100 mg|
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Humans and other mammals
Indication of Anakinra
For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Toxicity of Anakinra
Most common adverse reactions (incidence ? 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Anakinra on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.